In the world of multi-application platforms, performance is everything. From treatment time to clinical outcome and patient satisfaction, performance is the measure of success. It’s also the distinct difference of M22.
M22 is the gold standard platform for the treatment of skin conditions and hair removal. Used by physicians around the world, M22 is the multi-application platform that enables you to treat more types of patients and conditions with better outcomes.
M22 proudly adds the new ResurFX™ module for non-ablative fractional skin resurfacing. So now, in one device, practitioners have the ideal platform - the world’s best IPL module combined with the most affordable and effective non-ablative fractional module- ResurFX
|
|
Performance
M22 grows with your practice
Expand to your treatment needs and adapts to future applications as they emerge.
 Innovative - Rely on Lumenis, the most trusted and name in aesthetic devices.
Modular - Invest in smart, robust technology- 3 modules for superior clinical results.
Versatile - Treat more than 40 indications for use.
Validated - Clinically validated in over 80 peerreviewed papers.
Experienced - Easy to use- over 1,000 proprietary treatment parameters.
|
|
The Only Nd YAG with Multiple Sequential Plusing Technology
The Nd:YAG module of M22 offers treatments for telangiectasias, hemangiomas, leg veins and facial wrinkles.
Multiple Sequential Pulsing, which is available in both the Nd:YAG and IPL modules on M22, enables cooling between a sequence of pulses, to protect the epidermis while allowing the safe use of higher fluences. This enables safe treatment on all skin types, including darker skin, and reduces the chance of unwanted side effects in vascular lesion treatments.
|
How it works:
Light energy is delivered during the
pulses, and the tissue cools during
the delays. More energy is safely
delivered to the target.
What it does:
Multiple-Sequential Pulsing
allows for cooling between
pulses to safely remove hair on
all skin types including darker
skin and reduces the chance of
skin damage in vascular lesion
treatments.
|
 |
*The ResurFX module of M22 is available in the U.S. pending U.S. Food and Drug Administration (FDA) clearance.
